A double‐blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage of labour
Open Access
- 1 September 2000
- journal article
- clinical trial
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 107 (9) , 1111-1115
- https://doi.org/10.1111/j.1471-0528.2000.tb11109.x
Abstract
Objective To compare oral misoprostol 400 μg with intramuscular oxytocin 10 IU in the routine management of the third stage. Design Double‐blind placebo controlled trial. Setting Main referral hospital and its associated polyclinics in Accra, Ghana. Population Four hundred and one low risk women, in the second stage of labour with anticipated vaginal delivery, who entered labour spontaneously. Methods After delivery of the anterior shoulder of the baby, the women were randomised to receive either: 1. misoprostol 400 μg powder in water orally and 1 mL normal saline intramuscular injection (placebo); or 2. powdered cellulose in water orally (placebo) and 1 mL oxytocin 10 IU intramuscular injection. Main outcome measures Change in haemoglobin concentration from before delivery to 12 hours postpartum. Secondary outcomes included need for additional oxytocics, blood loss > 500 mL and > 1000 mL, operative intervention for postpartum haemorrhage, and side effects, including nausea, vomiting, diarrhoea, shivering and elevated temperature. Results Demographic characteristics were similar. There was no significant difference in change in haemoglobin concentration between the two groups (0.60 g/dL for misoprostol and 0.55 g/dL for oxytocin; relative difference 9.6%; 95% CI 20.5–39.6%; P= 0.54). There were no significant differences in secondary outcomes with the exception of shivering, which occurred more frequently in the misoprostol group (22.2%vs 5.7%; relative risk 4.73; 95% CI 2.31–9.68; P < 0.0001). Conclusions In low risk women oral misoprostol appears to be as effective in minimising blood loss in the third stage of labour as intramuscular oxytocin. Shivering was noted more frequently with misoprostol use, but no other side effects were noted. Misoprostol has great potential for use in the third stage of labour especially in developing countries.Keywords
This publication has 10 references indexed in Scilit:
- Misoprostol dose‐related shivering and pyrexia in the third stage of labourBJOG: An International Journal of Obstetrics and Gynaecology, 1999
- Rectal misoprostol in the prevention of postpartum hemorrhage: A placebo-controlled trialAmerican Journal of Obstetrics and Gynecology, 1998
- A randomised placebo controlled trial of oral misoprostol in the third stage of labourBJOG: An International Journal of Obstetrics and Gynaecology, 1998
- Randomized comparison of rectalmisoprostol with Syntometrine for management of third stage of laborActa Obstetricia et Gynecologica Scandinavica, 1998
- Medical Abortion With Oral Methotrexate and Vaginal MisoprostolPublished by Wolters Kluwer Health ,1997
- Routine oxytocin in the third stage of labour: a placebo controlled randomised trialBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Use of oral misoprostol in the prevention of postpartum haemorrhageBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Misoprostol for third stage of labourThe Lancet, 1996
- Hemorrhage, infection, toxemia, and cardiac disease, 1954-85: causes for their declining role in maternal mortality.American Journal of Public Health, 1988
- The effects of routine oxytocic administration in the management of the third stage of labour: an overview of the evidence from controlled trialsBJOG: An International Journal of Obstetrics and Gynaecology, 1988